Navigation Links
FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments
Date:11/9/2010

SILVER SPRING, Md., Nov. 9, 2010 /PRNewswire-USNewswire/ -- Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The study, based on the second annual review of the status of 1,551 postmarketing studies/clinical trials, showed that 40 percent of the postmarketing studies/clinical trials had been closed (either fulfilled or released) by FDA. Of the remaining 60 percent, most were in progress and on schedule or the final report has been submitted for FDA review.

The review, done under a contract with Booz Allen Hamilton, examined the backlog of industry postmarketing studies and clinical trials for FDA-approved drugs and biologics. The backlog was defined as all those postmarketing requirements (PMR) and postmarketing commitments (PMC) open when the Food and Drug Administration Amendments Act (FDAAA) was enacted on Sept. 27, 2007.

Under the FDAAA, the agency must annually report the status of the backlog of PMR and PMC for all approved drug and biological products. In addition, manufacturers of drugs and biologics are required to report to the FDA in a timely manner any serious safety issues that are identified from studies or other sources.

Key findings of the study include:

  • During the second annual review, the status of 591 PMR/PMCs changed. Nearly half (46 percent) of the PMR/PMCs were updated to fulfilled status, which reflects a significant effort by FDA staff to complete reviews of the large number of submitted final reports
    '/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
2. RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs
3. Nycomed to Accelerate Expansion in China Through Acquisition of Majority Stake in Guangdong Techpool Bio-Pharma
4. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
5. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
6. Survey Reveals Majority of Americans Hold onto Myths About What Causes Colds and How to Treat Them
7. Martek Biosciences Announces Agreement to Sell Majority of Winchester, Ky. Manufacturing Site
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
10. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
11. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... ... services, announced today that the latest issue of Inclusive™ magazine, its multimedia publication ... platforms. The digital edition of the new issue, Volume 6, Issue 2, as ...
(Date:7/30/2015)... ... 2015 , ... Western University of Health Sciences faculty, students and alumni were ... largest sports and humanitarian event in the world this year and the single biggest ... July 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd ... in taxpayer money to fund the state’s large prison system, which has amassed largely ... highest rates of incarceration. In light of President Obama’s recent reduction of non violent ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer ... treatment designed specifically for the elimination of excess tissue under the chin, referred ... the state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Center in Philadelphia have found that a signaling protein ... turned on in nearly all recurrent prostate cancers that ... up, the protein, called Stat5, may be a specific ... addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., ...
... and use caution when exiting transportation , , SUNDAY, Dec. 30 ... slush and ice of winter requires special walking tactics, health ... careful, particularly since we haven,t had this type of weather ... specialist at Mount Sinai,s Department of Orthopaedics in New York ...
... injuries can happen to kids if precautions are skipped, ... Winter sports provide kids with great exercise and fun, ... say pediatric trauma experts. , "We see a startling ... snowmobile crashes and beyond," Amy Teddy, manager of the ...
... to make a different kind of New Year,s resolution, ... America,s Blood Centers and blood transfusion recipients across,the country ... National Blood Donor Month., Each year, more than ... to a recent study by W. Riley (et al) ...
... Dec. 28 Grubb & Ellis,Healthcare REIT, Inc. has ... closed on December 21, 2007., Park Place Office ... 133,000 square feet on eight and a half,acres in ... constructed in 1987,1988, and 2002, respectively, and offer tenants ...
... 500 Jobs, HARRISBURG, Pa., Dec. 28 A ... of the Butler,Memorial Hospital that will include a new ... the Department of Community and,Economic Development announced today. The ... The state,s aid will come in the form ...
Cached Medicine News:Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 3Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3Health News:Pennsylvania Invests $13.4 Million to Kick Off Butler Memorial Hospital Expansion 2
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: